Skip to main content
OpenTrials
Completed

NCT Number: NCT00038974

Hepatitis C Antiviral Resistance in African-Americans

This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

University of California, San Francisco, San Francisco, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Age between 18 and 70 years at screening
  • Black/African American or White/Caucasian
  • Born in the United States
  • Quantifiable Serum HCV RNA
  • Hepatitis C genotype 1
  • Liver biopsy consistent with chronic hepatitis C
  • Negative urine pregnancy test
  • Males and Females must be using two reliable forms of effective contraception while on drug and during follow-up.

Exclusion:

  • Previous treatment with interferon or ribavirin
  • Positive test at screening for anti-HIV
  • Positive test for HBsAg
  • Alcohol consumption of more than two drinks/day
  • History of other chronic liver disease
  • Pregnant or breast-feeding women
  • Male partners of women who are pregnant or contemplating pregnancy
  • Neutrophil count <1000 cells/mm3
  • Hgb <11 g/dl in women or 12 g/dl in men
  • Platelet count <75,000 cells/mm3.
  • Thalassemia, spherocytosis, history of GI bleeding or those at increased risk of anemia
  • Serum creatinine level >1.5 times the upper limit of normal at screening or CrCl < 75cc/min
  • Current dialysis
  • Alcohol or drug abuse within 6 months
  • Current (<6 months)severe psychiatric disorder
  • History of immunologically mediated disease
  • Decompensated liver disease
  • High risk cardiovascular/coronary artery disease
  • Severe seizure disorder or anticonvulsant use
  • Solid organ or bone marrow transplantation
  • Thyroid disease poorly controlled on prescribed medications
  • History or other evidence of retinopathy
  • Chronic use of oral steroids
  • Inability or unwillingness to provide informed consent or abide by the study protocol

Treatment and study plan

Peginterferon alfa-2a

Drug

Ribavirin

Drug

Primary outcomes

  1. Sustained Virologic Response (SVR)

    Time frame: 24 weeks after therapy is discontinued

    The primary end point of therapy was an SVR that was definied as the absences of detectable HCV RNA in serum 24 weeks after therapy was stopped.

Sponsors and collaborators

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Nih

Collaborators

  • Hoffmann-La Roche
  • National Cancer Institute (NCI)
  • National Center for Advancing Translational Sciences (NCATS)
  • National Institute on Minority Health and Health Disparities (NIMHD)

Registry information

Official study title

Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C)

Important dates

Study start
2002
Primary completion
2004
Study completion
2005
First posted
Jun 10, 2002
Registry last updated
Aug 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.